DDX53 and neoplasm: In addition to MC38, CT26 (Supplementary Fig. 1c, d, and Supplementary Fig. 2d–i) and A20 (Supplementary Fig. 1c, d, and Supplementary Fig. 2j–o) tumor models also demonstrated the essential role of tumor cell-intrinsic IFN-I signaling, but not IFN-II signaling, in the context of CD47-SIRPα blockade therapy.